A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.
A 17-year-old is experiencing diffuse thinning, dandruff, body hair shedding, and other symptoms, possibly linked to seborrheic dermatitis or telogen effluvium. They are using ketoconazole shampoo and considering blood tests to check for thyroid issues or deficiencies.
A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
A 19-year-old female is experiencing significant hair loss, with symptoms including alternating hair colors and thinning body hair. She seeks advice on coping and potential treatments, with suggestions to consult a dermatologist and check thyroid and hormone levels.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
A young man with hypertrichosis has over 95% of his face covered in hair, sparking humorous comments about hair loss treatments like minoxidil and dutasteride. Users joke about transplanting his facial hair and discuss the challenges of his condition compared to typical balding.
Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.
The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.
User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
A 27-year-old male experienced rapid hair loss after dengue fever, which activated a balding gene. The doctor suggested platelet-rich plasma treatment for hair regrowth.
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."
Stemson raised $15M for hair cloning, with hopes it becomes a reality in 10-20 years. Users are hopeful and discuss using Minoxidil and finasteride in the meantime.
The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
A user trying to avoid an expensive hair transplant, and the replies suggesting they wait two years on treatment before deciding if they need a transplant or not.
A user shared their 12-month progress after a 3500-graft hair transplant at Heva Clinic in Istanbul, choosing not to use minoxidil or finasteride. The results were praised, with comments noting the natural look and significant improvement.
The conversation discusses Perez Hilton's hair loss despite having three hair transplants. Participants suggest that hair loss can continue after a transplant if maintenance treatments like finasteride and minoxidil are not used, and that transplanted hair can still be susceptible to loss.
The conversation discusses hair loss treatments, focusing on vitamin D and B12 deficiencies, and mentions using finasteride. It also suggests getting a biopsy to differentiate between MPB and other conditions.
A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.
A new hair cloning breakthrough suggests a potential cure for hair loss, though skepticism remains about its availability and cost. Users discuss the possibility of unlimited hair grafts for transplants and express hope for future developments.
The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.
The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Transgender hormone therapy, including Estradiol Valerate, Spironolactone, and Progesterone Micronized, can reverse male pattern baldness and improve hair health. The user shares their positive experience with hair regrowth after transitioning from male to female.